thiotepa has been researched along with Inflammation in 7 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome." | 9.09 | High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. ( Appelbaum, FR; Bensinger, W; Gutierrez-Delgado, F; Holmberg, LA; Hooper, H; Kawahara, K; Livingston, RB; Maziarz, RT; Montgomery, P; Rivkin, S; Weiden, P, 2000) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 7.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome." | 5.09 | High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. ( Appelbaum, FR; Bensinger, W; Gutierrez-Delgado, F; Holmberg, LA; Hooper, H; Kawahara, K; Livingston, RB; Maziarz, RT; Montgomery, P; Rivkin, S; Weiden, P, 2000) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 3.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Issell, BF | 1 |
| Prout, GR | 1 |
| Soloway, MS | 1 |
| Cummings, KB | 1 |
| Brannen, G | 1 |
| Veenema, R | 1 |
| Flanagan, M | 1 |
| Block, NL | 1 |
| Summers, JL | 1 |
| Levin, EA | 1 |
| Gutierrez-Delgado, F | 1 |
| Holmberg, LA | 1 |
| Hooper, H | 1 |
| Appelbaum, FR | 1 |
| Livingston, RB | 1 |
| Maziarz, RT | 1 |
| Weiden, P | 1 |
| Rivkin, S | 1 |
| Montgomery, P | 1 |
| Kawahara, K | 1 |
| Bensinger, W | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| Firstater, M | 1 |
| Meshorer, A | 1 |
| Tadmor, A | 1 |
| Itzicovitch, L | 1 |
| Schellhammer, PF | 1 |
| Portney, GL | 1 |
1 trial available for thiotepa and Inflammation
| Article | Year |
|---|---|
High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Chemotherapy, Adj | 2000 |
6 other studies available for thiotepa and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa.
Topics: Adult; Aged; Drug Evaluation; Humans; Inflammation; Middle Aged; Mitomycin; Mitomycins; Skin Disease | 1984 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |
The acute effects of various cytotoxic compounds injected into the prostate glands of dogs.
Topics: Animals; Antineoplastic Agents; Dactinomycin; Dogs; Ethoglucid; Fluorouracil; Inflammation; Injectio | 1978 |
Renal failure associated with the use of thio-tepa.
Topics: Acute Kidney Injury; Aged; Autopsy; Carcinoma, Transitional Cell; Humans; Inflammation; Male; Neopla | 1973 |
Bare sclera, scleral cautery and corticosteroid therapy of endemic pterygium in the Navajo Indian.
Topics: Arizona; Cautery; Disease Reservoirs; Eye Diseases; Follow-Up Studies; Humans; Indians, North Americ | 1969 |